IMC Chicago
RLMD icon

IMC Chicago’s Relmada Therapeutics RLMD Stock Holding History

IMC Chicago’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,350
Closed -$975K – 1328
2022
Q3 		$975K Buy
+26,350
New +$730K ﹤0.01% 939

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IMC Chicago's RLMD Position: Q4 2022 in Review

IMC Chicago sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 26,350 shares — an estimated $975K sold.

IMC Chicago first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $975K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • IMC Chicago reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • IMC Chicago sold 26,350 Relmada Therapeutics shares in Q4 2022, an estimated $975K.
  • IMC Chicago first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
  • IMC Chicago's Relmada Therapeutics position peaked at $975K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on IMC Chicago's 13F filing for Q4 2022, filed 9 Feb 2023.